Walter N Kernan Selected Research

Secondary Prevention

4/2024	Secondary Prevention in Patients With Stroke Versus Myocardial Infarction: Analysis of 2 National Cohorts.
1/2022	Efficacy of lower doses of pioglitazone after stroke or transient ischaemic attack in patients with insulin resistance.
1/2019	Pioglitazone Therapy in Patients With Stroke and Prediabetes: A Post Hoc Analysis of the IRIS Randomized Clinical Trial.
1/2018	Pioglitazone Prevents Stroke in Patients With a Recent Transient Ischemic Attack or Ischemic Stroke: A Planned Secondary Analysis of the IRIS Trial (Insulin Resistance Intervention After Stroke).
11/2017	Targeting Pioglitazone Hydrochloride Therapy After Stroke or Transient Ischemic Attack According to Pretreatment Risk for Stroke or Myocardial Infarction.
9/2016	Taking care of volunteers in a stroke trial: a new assisted-management strategy.
1/2015	The case for diet: a safe and efficacious strategy for secondary stroke prevention.
12/2014	Pioglitazone for secondary prevention after ischemic stroke and transient ischemic attack: rationale and design of the Insulin Resistance Intervention after Stroke Trial.
6/2012	The diagnosis and management of cerebrovascular disease in diabetes.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Walter N Kernan Research Topics

Disease

36	Stroke (Strokes) 04/2024 - 04/2003
21	Ischemic Stroke 09/2022 - 06/2003
19	Insulin Resistance 01/2022 - 06/2003
18	Transient Ischemic Attack 09/2022 - 06/2003
14	Myocardial Infarction 04/2024 - 07/2005
7	Cerebrovascular Disorders (Cerebrovascular Occlusion) 01/2018 - 01/2005
6	Diabetes Mellitus 01/2019 - 11/2004
5	Hypertension (High Blood Pressure) 01/2023 - 06/2003
5	Heart Failure 01/2022 - 01/2018
4	Cardiovascular Diseases (Cardiovascular Disease) 11/2023 - 05/2017
4	Bone Fractures (Bone Fracture) 01/2022 - 04/2016
3	Chronic Renal Insufficiency 11/2023 - 12/2018
3	Weight Gain 01/2022 - 04/2016
2	Metabolic Syndrome (Dysmetabolic Syndrome X) 11/2023 - 01/2019
2	Prediabetic State (Prediabetes) 01/2019 - 11/2004
2	Acute Coronary Syndrome 01/2019 - 05/2017
2	Vascular Diseases (Vascular Disease) 01/2019 - 01/2005
2	Edema (Dropsy) 01/2018 - 04/2016
2	Obesity 01/2018 - 06/2003
2	Cognitive Dysfunction 02/2005 - 04/2003
2	Glucose Intolerance 01/2005 - 11/2004
1	Lacunar Stroke 01/2024
1	Weight Loss (Weight Reduction) 11/2023
1	Type 2 Diabetes Mellitus (MODY) 01/2023
1	Dyslipidemias (Dyslipidemia) 01/2023
1	Atrial Fibrillation 01/2018
1	Dyspnea (Shortness of Breath) 01/2018
1	Unstable Angina 05/2017
1	Abdominal Obesity 07/2016
1	Intracranial Hemorrhages (Intracranial Hemorrhage) 07/2014
1	Hyperhomocysteinemia 01/2011
1	Intracranial Sinus Thrombosis (Sinus Thrombosis) 01/2011
1	Cerebral Hemorrhage 01/2011
1	Sickle Cell Anemia (Hemoglobin S Disease) 01/2011
1	Blood Vessel Dissection 01/2011
1	Patent Foramen Ovale 01/2011
1	Brain Diseases (Brain Disorder) 01/2005
1	Hemorrhagic Stroke 06/2003

Drug/Important Bio-Agent (IBA)

20	Pioglitazone (Actos)FDA Link 09/2022 - 06/2003
11	Insulin (Novolin)FDA Link 01/2019 - 06/2003
8	Glucose (Dextrose)FDA LinkGeneric 01/2019 - 06/2003
4	Estrogens (Estrogen)FDA Link 11/2005 - 04/2003
3	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 04/2024 - 11/2004
2	Sodium-Glucose Transporter 2 InhibitorsIBA 12/2018 - 12/2018
2	Glucagon-Like Peptide 1 (GLP 1)IBA 12/2018 - 12/2018
2	C-Reactive ProteinIBA 01/2018 - 07/2005
2	Caffeine (No Doz)FDA LinkGeneric 09/2005 - 06/2003
1	LDL Lipoproteins (beta Lipoproteins)IBA 04/2024
1	Biomarkers (Surrogate Marker)IBA 01/2024
1	glimepiride (Amarel)FDA LinkGeneric 01/2023
1	4- (2- (4- hydroxybenzyl)- phenoxy)- N- methylbutylamineIBA 01/2023
1	empagliflozinIBA 01/2023
1	LinagliptinIBA 01/2023
1	AnticoagulantsIBA 01/2023
1	Hemoglobins (Hemoglobin)IBA 01/2019
1	Sodium-Glucose Transport ProteinsIBA 12/2018
1	SodiumIBA 12/2018
1	SmokeIBA 10/2017
1	HDL LipoproteinsIBA 07/2016
1	Triglycerides (Triacylglycerol)IBA 07/2016
1	Therapeutic UsesIBA 01/2015
1	2,4-thiazolidinedione (thiazolidinedione)IBA 12/2014
1	Matrix Metalloproteinase 2 (Gelatinase A)IBA 07/2014
1	Matrix Metalloproteinases (MMPs)IBA 07/2014
1	Hormones (Hormone)IBA 01/2011
1	Platelet Aggregation Inhibitors (Antiplatelet Drugs)IBA 01/2011
1	CholesterolIBA 10/2010
1	HDL CholesterolIBA 07/2005
1	Estradiol (Delestrogen)FDA LinkGeneric 02/2005
1	Hypoglycemic Agents (Hypoglycemics)IBA 01/2005
1	candesartan cilexetil (Amias)FDA Link 12/2003
1	Nicotine FDA Link 06/2003
1	Blood Glucose (Blood Sugar)IBA 06/2003
1	Cocaine (Cocaine HCl)IBA 06/2003

Therapy/Procedure

15	Therapeutics 04/2024 - 12/2003
9	Secondary Prevention 04/2024 - 06/2012
3	Glycemic Control 06/2012 - 11/2004
1	Drug Tapering 01/2018
1	Diet Therapy (Therapy, Diet) 01/2015
1	Hysterectomy 04/2003